Current and novel therapeutic options for irritable bowel syndrome management

Digestive and Liver Disease

Volumn 41, Issue 12, 2009, Pages 854-862

  Camilleri, M ^a   Andresen, V ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b ISRAELITISCHES KRANKENHAUS   (Germany)

Author keywords

Clinical trials; Opioids; Pharmacodynamics; Pharmacology; Serotonergics

Indexed keywords

ALOSETRON; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BENZODIAZEPINE DERIVATIVE; BILE ACID SEQUESTRANT; BISACODYL; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIPHENOXYLATE; DOCUSATE SODIUM; IMMUNOMODULATING AGENT; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; MELATONIN; NEUROTRANSMITTER; OPIATE; PLACEBO; PREGABALIN; PROBIOTIC AGENT; RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AUTONOMIC DYSFUNCTION; BLOATING; BRAIN FUNCTION; CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INCIDENCE; INTESTINE FUNCTION; IRRITABLE COLON; MUCOSAL IMMUNITY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SHORT SURVEY; SOCIAL ASPECT; WESTERN HEMISPHERE;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 70350567652     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.07.009     Document Type: Short Survey

References (134)

1. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38 (1993) 1569-1580
2. Cremonini F., and Talley N.J. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 34 (2005) 189-204
3. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 123 (2002) 2108-2131
4. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 17 (2005) 311-316
5. Dunlop S.P., Coleman N.S., Blackshaw E., et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3 (2005) 349-357
6. Bearcroft C.P., Perrett D., and Farthing M.J. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42 (1998) 42-46
7. Houghton L.A., Atkinson W., Whitaker R.P., et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 52 (2003) 663-670
8. Roka R., Rosztoczy A., Leveque M., et al. A pilot study of fecal serine-protease activity: a pathophysiological factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 5 (2007) 550-555
9. Borman R. Serotonergic modulation and irritable bowel syndrome. Expert Opin Emerg Drugs 6 (2001) 57-68
10. Spiller R.C. Postinfectious irritable bowel syndrome. Gastroenterology 124 (2003) 1662-1671
11. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47 (2000) 804-811
12. Spiller R.C. Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2 (2004) 445-455
13. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126 (2004) 693-702
14. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005) 541-551
15. Aerssens J., Camilleri M., Talloen W., et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6 (2008) 194-205
16. Gershon M.D. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13 Suppl. 2 (1999) 15-30
17. Gershon M.D. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20 Suppl. 7 (2004) 3-14
18. Hicks G.A., Coldwell J.R., Schindler M., et al. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol 544 Pt 3 (2002) 861-869
19. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 16 (2009) 53-59
20. Gershon M.D. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 3 (2003) 600-607
21. Coates M.D., Mahoney C.R., Linden D.R., et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126 (2004) 1657-1664
22. Andrews C., Camilleri M., Bharucha A.E., et al. Serotonin-transporter (SERT) polymorphism genotype and SERT expression in mucosal biopsies of patients with irritable bowel syndrome. Gastroenterology 130 (2006) A24 [abstract]
23. Gunput M.D. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 13 Suppl. 2 (1999) 70-76
24. Mayer E.A., Berman S., Derbyshire S.W., et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16 (2002) 1357-1366
25. Andresen V., Montori V.M., Keller J., et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6 (2008) 545-555
26. El-Serag H.B., Olden K., and Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 16 (2002) 1171-1185
27. Coleman N.S., Marciani L., Blackshaw E., et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 18 (2003) 1039-1048
28. Paterson W.G., Ford D., Ganguli S.C., et al. A novel, oral 5HT3 partial agonist, DDP733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study. Gastroenterology 134 (2008) A546-A547 [abstract]
29. Evans B.W., Clark W.K., Moore D.J., et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev (2007) CD003960
30. Camilleri M., Vazquez-Roque M.I., Burton D., et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19 (2007) 30-38
31. Bouras E.P., Camilleri M., Burton D.D., et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120 (2001) 354-360
32. Camilleri M., Kerstens R., Rykx A., et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358 (2008) 2344-2354
33. Tack J., Van Outryve M., Beyens G., et al. Prucalopride (Resolor(R) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut (2008) [November 5, Epub ahead of print]
34. Quigley E.M., Vandeplassche L., Kerstens R., et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29 (2009) 315-328
35. Camilleri M., Kerstens R., Beyens G., et al. A double-blind, placebo-controlled trial to evaluate the safety and tolerability of prucalopride oral solution in constipated elderly patients living in a nursing facility. Gastroenterology 136 Suppl. 1 (2009) 240
36. Smith J.A., Beattie D.T., Marquess D., et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 125-137
37. Beattie D.T., Armstrong S.R., Shaw J.P., et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 139-147
38. Camilleri M., Manini M., McKinzie S., et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 20 Suppl. 2 (2008) 6 [abstract]
39. 4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 134 (2008) A 545
40. Gorard D.A., Libby G.W., and Farthing M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8 (1994) 159-166
41. Tack J. A placebo controlled trial of buspirone, a fundus relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor functions. Gastroenterology 116 (2000) G1423
42. Chial H.J., Camilleri M., Ferber I., et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 1 (2003) 211-218
43. Vahedi H., Merat S., Rashidioon A., et al. Effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 22 (2005) 381-385
44. Vahedi H., Merat S., Momtahen S., et al. Clinical trial: effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 27 (2008) 678-684
45. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut (2008) [November 10, Epub ahead of print]
46. Bergmann M., Heddergott A., and Schlosser T. Die therapie des colon irritabile mit trimaprimin (Herphonal)-Eine kontrollierte studie. Z Klin Med 46 (1991) 1621-1628
47. Goyal R.K. Muscarinic receptor subtypes. Physiology and clinical implications. N Engl J Med 321 (1989) 1022-1029
48. Eglen R.M. Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci 68 (2001) 2573-2578
49. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Br Med J (2008) [November 13, Epub ahead of print]
50. Poynard T., Regimbeau C., and Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15 (2001) 355-361
51. Kobayashi S., Ikeda K., Suzuki M., et al. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn J Pharmacol 86 (2001) 281-288
52. Foote J., Glavind K., Kralidis G., et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 48 (2005) 471-477
53. Houghton L.A., Rogers J., Whorwell P.J., et al. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 11 (1997) 561-568
54. Bharucha A.E., Camilleri M., Zinsmeister A.R., et al. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 273 5 Pt 1 (1997) G997-1006
55. Malcolm A., Phillips S.F., Camilleri M., et al. Pharmacological modulation of rectal tone alters perception of distention in humans. Am J Gastroenterol 92 (1997) 2073-2079
56. Malcolm A., Camilleri M., Kost L., et al. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 14 (2000) 783-793
57. Camilleri M., Kim D.Y., McKinzie S., et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 1 (2003) 111-121
58. Lee K.J., Kim J.H., and Cho S.W. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 22 (2005) 981-988
59. Houghton L.A., Fell C., Whorwell P.J., et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56 (2007) 1218-1225
60. Borody T.J., Quigley E.M., Phillips S.F., et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology 89 (1985) 562-570
61. Steadman C.J., Phillips S.F., Camilleri M., et al. Control of muscle tone in the human colon. Gut 33 (1992) 541-546
62. Lembo T., Naliboff B.D., Matin K., et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 87 (2000) 137-147
63. Delvaux M., Louvel D., Lagier E., et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116 (1999) 38-45
64. Delgado-Aros S., Chial H.J., Cremonini F., et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 18 (2003) 507-514
65. Delvaux M., Beck A., Jacob J., et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 20 (2004) 237-246
66. Szarka L.A., Camilleri M., Burton D., et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 5 (2007) 1268-1275
67. Mangel A.W., Bornstein J.D., Hamm L.R., et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28 (2008) 239-249
68. Wolff B.G., Michelassi F., Gerkin T.M., et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 240 (2004) 728-734 [discussion 734-5]
69. Taguchi A., Sharma N., Saleem R.M., et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 345 (2001) 935-940
70. Delaney C.P., Weese J.L., Hyman N.H., et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 48 (2005) 1114-1125 [discussion 1125-6; author reply 1127-9]
71. Gonenne J., Camilleri M., Ferber I., et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 784-791
72. Foxx-Orenstein A.E., Camilleri M., Szarka L.A., et al. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. Neurogastroenterol Motil 19 (2007) 821-830
73. Yuan C.S., Doshan H., Charney M.R., et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45 (2005) 538-546
74. Yuan C.S., Foss J.F., O'Connor M., et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. J Am Med Assoc 283 (2000) 367-372
75. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43 (1991) 425-473
76. Tache Y., Monnikes H., Bonaz B., et al. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann N Y Acad Sci 697 (1993) 233-243
77. Greenwood-Van Meerveld B., Johnson A.C., Cochrane S., et al. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil 17 (2005) 415-422
78. Monnikes H., Schmidt B.G., and Tache Y. Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology 104 (1993) 716-723
79. Sagami Y., Shimada Y., Tayama J., et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53 (2004) 958-964
80. Sweetser S.R., Linker Nord S.J., Burton D.D., et al. Effects of a novel corticotrophin releasing factor receptor-1 antagonist, BMS-562086, on gastrointestinal and colonic transit and bowel habits in patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 134 (2008) A 548
81. Leventer S.M., Kucharik R.F., Keogh J.C., et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 99 (2004) S 279
82. Leventer S.M., Raudibaugh K., Frissora C.L., et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 27 (2008) 197-206
83. Storr M., Koppitz P., Sibaev A., et al. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 33 (2002) 101-108
84. Barajas-Lopez C., Peres A.L., Espinosa-Luna R., et al. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus. Eur J Pharmacol 312 (1996) 319-325
85. +-channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can J Physiol Pharmacol 78 (2000) 799-806
86. Lu W.Z., Gwee K.A., Moochhalla S., et al. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 22 (2005) 927-934
87. Song G.H., Leng P.H., Gwee K.A., et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 54 (2005) 1402-1407
88. Walsh J.H. Gastrointestinal hormones. Physiology of the gastrointestinal tract. 3rd ed. (1994), Raven, New York 49-67
89. Chey W.Y., Jin H.O., Lee M.H., et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 96 (2001) 1499-1506
90. Wank S.A. Cholecystokinin receptors. Am J Physiol 269 5 Pt 1 (1995) G628-G646
91. Fourmy D., Escrieut C., Archer E., et al. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists. Pharmacol Toxicol 91 (2002) 313-320
92. D'Amato M., and Rovati L.C. Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders. Expert Opin Investig Drugs 6 (1997) 819-836
93. Meyer B.M., Werth B.A., Beglinger C., et al. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 2 (1989) 12-15
94. Cann P.A., Rovati L.C., Smart H.L., et al. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Ann N Y Acad Sci 713 (1994) 449-450
95. D'Amato M., Whorwell P.J., and Thompson D.G. The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut 45 Suppl. V (1999) A258
96. Pharmabiz.com. Forest to discontinue development in U.S. of dexloxiglumide for irritable bowel syndrome. Pharmabiz.com 2004;October:http://www.pharmabiz.com/article/detnews.asp?articleid=18255§ionid=14.
97. Cremonini F., Camilleri M., McKinzie S., et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 100 (2005) 652-663
98. Whorwell P.J., Pace F., D'Amato M., et al. A phase III, 6-month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK-1 antagonist dexloxiglumide in constipation-predominant IBS: the Darwin study. Gastroenterology 134 (2008) A-157 [abstract]
99. O'Donnell L.J., Watson A.J., Cameron D., et al. Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome. Aliment Pharmacol Ther 4 (1990) 177-181
100. von der Ohe M.R., Camilleri M., Thomforde G.M., et al. Differential regional effects of octreotide on human gastrointestinal motor function. Gut 36 (1995) 743-748
101. Schwetz I., Naliboff B., Munakata J., et al. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 19 (2004) 123-131
102. Bradette M., Delvaux M., Staumont G., et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 39 (1994) 1171-1178
103. Holzer P., and Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 73 (1997) 173-217
104. Moriarty D., Selve N., Baird A.W., et al. Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation. Am J Physiol Cell Physiol 280 (2001) C852-C858
105. Onori L., Aggio A., Taddei G., et al. Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon. Am J Physiol Gastrointest Liver Physiol 278 (2000) G137-G147
106. Oh-Young L., Manakata J., and Naliboff B. A double-blind, parallel group pilot study of the effects o CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 118 (2000) A 846
107. Lordal M., Navalesi G., Theodorsson E., et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 134 (2001) 215-223
108. Houghton L.A., Cremonini F., Camilleri M., et al. Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 19 (2007) 732-743
109. 3 receptor antagonist, talnetant SB223242 on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled, dose-ranging trials. Gastroenterology 132 (2007) A60
110. Lubiprostone: RU 0211, SPI 0211. Drugs R D 6 (2005) 245-258
111. Camilleri M., Bharucha A.E., Ueno R., et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol 290 (2006) G942-G947
112. Johanson J.F., Gargano A.M., Holland P.C., et al. Phase III, efficacy and safety of RU-0211 a novel chloride channel activator, for the treatment of constipation. Gastroenterology 124 (2003) A48
113. Johanson J.F., Gargano M.A., Holland P.C., et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology 126 4 Suppl. 2 (2004) A-100
114. Johanson J.F., Gargano M., and Patchen M. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Gastroenterology 122 4 Suppl. 1 (2002) A-315
115. Johanson J.F., Drossman D.A., Panas R., et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27 (2008) 685-696
116. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29 (2009) 329-341
117. Currie M.G., Fok K.F., Kato J., et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 89 (1992) 947-951
118. Hamra F.K., Forte L.R., Eber S.L., et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 90 (1993) 10464-10468
119. Giannella R.A. Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do?. J Lab Clin Med 125 (1995) 173-181
120. Forte L.R. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 81 (1999) 25-39
121. Currie M.G., Kurtz C., Mahajan-Miklos S., et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol 100 (2005) S-328 [abstract]
122. Johnston J.M., Kurtz C.B., Drossman D.A., et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104 (2009) 125-132
123. Mangel A.W., and Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 78 (2008) 180-186
124. Verdu E.F., and Collins S.M. Irritable bowel syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol 21 (2005) 697-701
125. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut (2008) [online first, published on December 17]
126. Pimentel M., Chow E.J., and Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98 (2003) 412-419
127. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145 (2006) 557-563
128. Lembo A., Zakko S.F., Ferreira N.L., et al. Rifaximin for treatment of diarrhea-associated irritable bowel syndrome: short-term treatment leading to long-term sustained response. Gastroenterology 134 (2008) A-545 [abstract]
129. Leri O., Tubili S., De Rosa F.G., et al. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammo-pharmacology 5 (1997) 153-158
130. Grazioli I., Melzi G., Balsamo V., et al. Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet. Minerva Pediatr 45 (1993) 253-258
131. Miehlke S., Madisch A., Bethke B., et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 135 (2008) 1510-1516
132. Bonderup O.K., Hansen J.B., Teglbjaerg P.S., et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 58 (2009) 68-72
133. Chande N., Macdonald J.K., and McDonald J.W. Interventions for treating microscopic colitis: a Cochrane inflammatory bowel disease and functional bowel disorders review group systematic review of randomized trials. Am J Gastroenterol 104 (2009) 235-241
134. Barbara G., Cremon C., Gargano L., et al. Mesalazine treatment for intestinal immune activation in patient with irritable bowel syndrome: a randomized controlled pilot trial. Gastroenterology 134 (2008) A-546 [abstract]